BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,096 filers reported holding BAXTER INTL INC in Q4 2020. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,321,882 | -23.6% | 35,026 | -7.7% | 0.12% | -19.6% |
| Q2 2023 | $1,729,321 | +10.7% | 37,957 | -1.4% | 0.14% | +0.7% |
| Q1 2023 | $1,561,601 | -27.3% | 38,501 | -8.6% | 0.14% | -32.1% |
| Q4 2022 | $2,146,958 | -8.7% | 42,122 | -3.5% | 0.21% | -15.0% |
| Q3 2022 | $2,352,000 | -15.7% | 43,665 | +0.6% | 0.25% | -13.1% |
| Q2 2022 | $2,789,000 | -16.7% | 43,404 | +0.6% | 0.28% | -3.4% |
| Q1 2022 | $3,348,000 | -9.6% | 43,164 | +0.1% | 0.29% | -5.5% |
| Q4 2021 | $3,702,000 | +5.9% | 43,134 | -0.8% | 0.31% | -4.3% |
| Q3 2021 | $3,497,000 | -0.3% | 43,480 | -0.2% | 0.32% | -3.0% |
| Q2 2021 | $3,508,000 | -5.8% | 43,580 | -1.3% | 0.33% | -10.2% |
| Q1 2021 | $3,725,000 | +6.4% | 44,173 | +1.3% | 0.37% | -8.4% |
| Q4 2020 | $3,500,000 | +0.6% | 43,623 | +0.8% | 0.41% | -12.5% |
| Q3 2020 | $3,479,000 | -6.2% | 43,273 | +0.5% | 0.46% | -10.6% |
| Q2 2020 | $3,707,000 | +6.3% | 43,056 | +0.3% | 0.52% | -11.7% |
| Q1 2020 | $3,486,000 | -3.6% | 42,925 | -0.8% | 0.59% | +21.7% |
| Q4 2019 | $3,618,000 | -5.1% | 43,260 | -0.7% | 0.48% | -14.1% |
| Q3 2019 | $3,813,000 | +8.0% | 43,586 | +1.2% | 0.56% | +3.1% |
| Q2 2019 | $3,529,000 | -6.3% | 43,076 | -7.0% | 0.54% | -7.3% |
| Q1 2019 | $3,766,000 | +16.0% | 46,301 | -6.1% | 0.59% | +2.6% |
| Q4 2018 | $3,246,000 | -15.2% | 49,299 | -0.8% | 0.57% | -3.5% |
| Q3 2018 | $3,830,000 | +2.8% | 49,677 | -1.5% | 0.59% | -8.3% |
| Q2 2018 | $3,727,000 | +7.7% | 50,458 | -5.2% | 0.65% | +1.7% |
| Q1 2018 | $3,460,000 | -11.3% | 53,208 | -11.8% | 0.64% | -11.5% |
| Q4 2017 | $3,899,000 | +1.2% | 60,318 | -1.8% | 0.72% | -6.0% |
| Q3 2017 | $3,852,000 | -6.5% | 61,393 | -9.7% | 0.77% | -6.7% |
| Q2 2017 | $4,118,000 | +13.1% | 68,024 | -3.1% | 0.82% | +10.8% |
| Q1 2017 | $3,641,000 | +19.5% | 70,202 | +2.2% | 0.74% | +6.9% |
| Q4 2016 | $3,046,000 | -9.4% | 68,693 | -2.8% | 0.69% | -10.0% |
| Q3 2016 | $3,363,000 | +0.1% | 70,647 | -4.9% | 0.77% | +0.3% |
| Q2 2016 | $3,358,000 | +11.3% | 74,274 | +1.1% | 0.77% | +1.6% |
| Q1 2016 | $3,018,000 | +5.5% | 73,483 | -2.0% | 0.76% | +0.1% |
| Q4 2015 | $2,861,000 | +15.5% | 74,985 | -0.5% | 0.76% | +8.6% |
| Q3 2015 | $2,477,000 | -54.3% | 75,360 | -2.9% | 0.70% | -49.9% |
| Q2 2015 | $5,425,000 | +0.6% | 77,582 | -1.4% | 1.39% | +1.7% |
| Q1 2015 | $5,392,000 | -4.2% | 78,703 | +2.5% | 1.36% | -5.9% |
| Q4 2014 | $5,629,000 | -0.3% | 76,801 | -2.3% | 1.45% | -4.9% |
| Q3 2014 | $5,644,000 | -1.0% | 78,631 | -0.3% | 1.52% | +22.9% |
| Q2 2014 | $5,701,000 | +0.0% | 78,844 | +1.8% | 1.24% | -5.3% |
| Q1 2014 | $5,700,000 | +1.5% | 77,478 | -4.0% | 1.31% | -14.2% |
| Q4 2013 | $5,614,000 | +21.1% | 80,685 | +14.3% | 1.52% | +10.3% |
| Q3 2013 | $4,637,000 | -3.2% | 70,612 | +2.1% | 1.38% | -12.9% |
| Q2 2013 | $4,792,000 | – | 69,164 | – | 1.59% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |